PRAX – praxis precision medicines, inc. (US:NASDAQ)
Stock Stats
News
Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome [Yahoo! Finance]
Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.
GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners [Yahoo! Finance]
Praxis Precision Medicines to Present at Upcoming December Investor Conferences
Form 4 Praxis Precision Medicin For: Nov 14 Filed by: Mastrocola Lauren
Form 4 Praxis Precision Medicin For: Nov 14 Filed by: Kelly Timothy Edwin
Form 4 Praxis Precision Medicin For: Nov 14 Filed by: Mastrocola Lauren
Form 4 Praxis Precision Medicin For: Nov 14 Filed by: Nemiroff Alex
Form SC 13G/A Praxis Precision Medicin Filed by: Point72 Asset Management, L.P.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.